欧美成人动漫日韩国庆_亚洲天堂自拍偷拍_人妻少妇边接电话边娇喘_新婚少妇交换杨雨婷_高清不卡一区二区在线观看_亚洲国产中文另类久久久精品网站_十八禁裸体自慰免费观看_日本亚洲中文有码_日本人zzzwww色视频直播_国产福利姬在线观看

Ribo's clinical application for new oligonucleotide therapeutics in the treatment of type 2 diabetes got approved

Recently, the Center for Drug Evaluation, National Medical Products Administration completed the technical review on the application for a clinical trial of a new oligonucleotide therapeutics for the treatment of type 2 diabetes submitted by Suzhou Ribo Life Science Co., Ltd., and issued the Notice for Clinical Trial.

The clinical application of Suzhou Ribo for new drug for treatment of type 2 diabetes got accepted by CDE

Recently, Center for Drug Evaluation, National Medical Products Administration officially accepted the clinical trial application of imported drug ISIS449884 Injection submitted by Suzhou Ribo Life Science Co. Ltd.,. This product belongs to Class 1 innovative drug not marketed in China or abroad, and the proposed indication is type 2 diabetes.

Phase II/III study of optic neuroprotective oligonucleotide therapeutics QPI-1007 completed dosing of the first subject in China

Kunshan RiboQuark Pharmaceutical Technology Co. Ltd. announced that in the global pivotal II/III study QRK207 of its innovative siRNA drug QPI-1007 for optic nerve protection, the investigational product has been administered to the first subject by Professor Wang Ningli's team at Beijing Tongren Hospital, Capital Medical University, China.

Ribo successfully raised 270 million yuan in its Series B financing

On April 21, 2017, Suzhou Ribo Life Science Co., Ltd. announced the successful completion of Series B private equity financing of RMB 270 million (about $40 million), which introduced strong capital support for developing China's oligonucleotide pharmaceutical industry.

Ribo launched a strategic collaboration with global oligonucleotide pharmaceutical giant, Ionis, USA

Suzhou Ribo Life Science Co. Ltd., announced today a partnership with the global oligonucleotide pharmaceutical giant Ionis Pharmaceutical Inc. (Nasdaq code: IONS). Furthermore, it signed cooperation and licensing agreements to work together to promote the R&D and commercialization of oligonucleotide pharmaceuticals (or RNA-targeted drugs) in China.